15.85USD+0.51%Mkt Cap: —P/E: —1d ago
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immu…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value370.87M $
Revenue (TTM)53.74M $
Gross Profit39.39M $
Net Income (TTM)33.79M $
Revenue/Share3.622 USD
Last Price15.85 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA17.00
EV/Revenue6.90
P/S—
P/B3.56
EPS (TTM)-0.05
EPS (Forward)—
52W Range
15.0555% of range16.50
52W High16.50 USD
52W Low15.05 USD
Profitability
Gross Margin73.30%
Oper. Margin39.94%
EBITDA Margin40.60%
Profit Margin62.87%
ROE72.14%
ROA14.74%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.83M $
CapEx (TTM)—
FCF Margin36.09%
FCF Yield—
Net Debt-100.97M $
Net Debt/EBITDA-4.63
Balance Sheet
Debt/Equity5.00
Current Ratio20.30
Quick Ratio19.78
Book Value/Sh4.462 USD
Cash/Share3.570 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split0.055556:1
Split DateMar 26, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.37.31M
Float14.47M
Insiders2.82%
Institutions76.14%
Technical
SMA 500.6630 (+2290.5%)
SMA 2000.8770 (+1707.2%)
Beta-0.33
S&P 52W Chg18.16%
Avg Vol (30d)774
Avg Vol (10d)3.86K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—